Physician profile
Philip Mark Fiore
NPI 1306826581
$3,360.00
in general payments reported to CMS, 2019-2025
15 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $353 · 2021: $553 · 2022: $708 · 2023: $512 · 2024: $435 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,241.42 | 2019-2025 | Idosetr |
| Aerie Pharmaceuticals, INC. | $318.94 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $291.59 | 2019-2023 | Cequa, Ilumya |
| Bausch & Lomb Americas INC. | $273.46 | 2022-2023 | Vyzulta, Prolensa, Lotemax Sm |
| Kala Pharmaceuticals, INC. | $219.42 | 2019-2022 | |
| Biotissue Holdings INC. | $212.85 | 2023-2025 | |
| Allergan, INC. | $184.70 | 2020-2021 | |
| Alcon Vision LLC | $136.39 | 2022 | |
| Dompe US, INC. | $107.63 | 2023 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $107.47 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.43 | 2019-2021 | |
| Thea Pharma INC. | $79.79 | 2024-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $43.32 | 2022-2023 | Dextenza |
| Oyster Point Pharma, INC. | $30.19 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Fiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.